Myocardial Protection With Histidine-Tryptophan- Ketoglutarate (HTK) Solution in Comparison With Hypothermic Hyperkalemic Blood (HHB) Solution in The Correction of Acyanotic Congenital Heart Diseases.
Not Applicable
- Conditions
- Anaesthesia
- Registration Number
- PACTR202109777317416
- Lead Sponsor
- Faculty of medicine at Ain Shams university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Acyanotic congenital heart diseases undergoing total repair under cardiopulmonary bypass.
Aged from 6 months to 2 years of both sexes.
Scheduled for elective operations.
Exclusion Criteria
Reoperation.
Scheduled for palliative surgeries.
Undergoing emergency surgeries.
Patients with reduced left ventricular function, determined by left ventricular ejection fraction less than 40%.
Patients with renal or liver impairment, determined by elevated creatinine levels or liver enzymes ‘AST and ALT’ more than normal values for age.
Patients with any neurological dysfunction as epilepsy and cerebral palsy (CP).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method evel of Troponins
- Secondary Outcome Measures
Name Time Method The left ventricular ejection fraction (EF %).;The left ventricular fractional shortening FS.;The maximum vasoactive inotropic score VIS. The VIS was calculated according to Gaies et al study as follows: VIS= dopamine dose (mcg/kg/min) + dobutamine dose (mcg/kg/min) + 100 x epinephrine dose (mcg/kg/min) +10 x milrinone dose (mcg/kg/min) + 10,000 x vasopressin dose (U/kg/min) + 100 x norepinephrine dose (mcg/kg/min);ICU length of stay;Hospital length of stay ;Incidence of prolonged postoperative mechanical ventilation.